Hepatitis D, Chronic Clinical Trial
Official title:
Pegylated Interferon Alone or in Combination With Ezetimibe for Patients With Chronic Hepatitis D
Ezetimibe possesses pharmacophore features to inhibit NTCP, the receptor required for HBV
and HDV hepatocyte entry, that include two hydrophobes and one hydrogen bond acceptor.
The aim of the study io evaluate the utility of Ezetimibe in combination with pegylated
interferon in patients with chronic HDV infection.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05461170 -
SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection.
|
Phase 2 | |
| Active, not recruiting |
NCT04535544 -
A Study of JNJ-73763989 + Nucleos(t)Ide Analog in Participants Co-Infected With Hepatitis B and Hepatitis D Virus
|
Phase 2 | |
| Completed |
NCT02732639 -
A Study of Pegylated Interferon (PEG-IFN) Alfa-2a (Pegasys) in Participants With Chronic Hepatitis D (CHD)
|
Phase 3 | |
| Completed |
NCT02731131 -
A Study of Peginterferon Alfa-2a With or Without Ribavirin in Participants With Chronic Hepatitis D (CHD)
|
Phase 2 | |
| Completed |
NCT02765802 -
A Study to Evaluate Pegylated Interferon Lambda Monotherapy in Patients With Chronic Hepatitis Delta Virus Infection
|
Phase 2 | |
| Active, not recruiting |
NCT05229991 -
Once Daily Dosing of Lonafarnib Co-administered With Ritonavir for Treatment of Chronic Hepatitis D Virus Infection
|
Phase 3 | |
| Terminated |
NCT01861444 -
An Observational Study on the Prevalence of Chronic Hepatitis D in Romania and the Efficacy of Treatment With Pegasys (Peginterferon Alfa-2a)
|
N/A | |
| Recruiting |
NCT04166266 -
Observatory of Efficacy and Safety of Bulevirtide in Patients With Chronic HBV/HDV Co-infection
|
||
| Completed |
NCT01088659 -
A Study of Pegasys (Peginterferon Alfa 2a) Alone or in Combination With Tenofovir in Patients With Chronic Hepatitis D.
|
Phase 3 | |
| Completed |
NCT00686790 -
Efficacy of Peginterferon Alfa-2b in Previously Untreated Subjects With Chronic Hepatitis B and D Co-infection (Study P04603)
|
Phase 3 | |
| Completed |
NCT02876419 -
A Long Term Follow-up Study of Patients From the REP 301 Protocol
|